Vanguard Global Advisers
JSPR icon

Vanguard Global Advisers’s Jasper Therapeutics JSPR Stock Holding History

Vanguard Global Advisers’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,972
Closed -$3.48K – 3693
2026
Q1 		$3.48K Buy
+3,972
New +$5.51K ﹤0.01% 3583

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Global Advisers's JSPR Position: Q2 2026 in Review

Vanguard Global Advisers sold out of Jasper Therapeutics (JSPR) in Q2 2026, closing a stake of 3,972 shares — an estimated $3.48K sold.

Vanguard Global Advisers first reported a position in JSPR in Q1 2026 and held it in 1 quarter. The position peaked at $3.48K in Q1 2026. 41 funds tracked by Wall St. Rank hold JSPR as of Q2 2026.

  • Vanguard Global Advisers reported no remaining Jasper Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Vanguard Global Advisers sold 3,972 Jasper Therapeutics shares in Q2 2026, an estimated $3.48K.
  • Vanguard Global Advisers first reported a position in Jasper Therapeutics in Q1 2026 and held it in 1 quarter.
  • Vanguard Global Advisers's Jasper Therapeutics position peaked at $3.48K in Q1 2026.
  • 41 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.